

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10165-006

APPLICATION NO.

09/547,220

APPLICANT

Brines et al.

FILING DATE

April 11, 2000

GROUP

1647

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|-----------------|----------|------------------|-------|----------|-------------------------------|
| RW | AA | 5,888,772 | 3/30/99 | Okasinski et al. | 435 | 435 | RECEIVED |
| | AB | 5,856,298 | 1/5/99 | Strickland | 514 | 8 | |
| | AC | 5,835,382 | 11/10/98 | Wilson et al. | 364 | 49 | 2000 |
| | AD | 5,830,851 | 11/3/98 | Wrighton et al. | 514 | 2 | TECH CENTER |
| | AE | 5,773,569 | 6/30/98 | Wrighton et al. | 530 | 300 | 2000 |
| | AF | 5,767,078 | 6/16/98 | Johnson et al. | 514 | 12 | |
| | AG | 5,714,459 | 2/3/98 | O'Brien | 514 | 2 | |
| | AH | 5,700,909 | 12/23/97 | O'Brien | 530 | 326 | |
| | AI | 5,696,080 | 12/9/97 | O'Brien | 514 | 2 | |
| | AJ | 5,661,125 | 8/26/97 | Strickland | 514 | 8 | |
| | AK | 5,621,080 | 4/15/97 | Lin | 530 | 350 | |
| | AL | 5,614,184 | 3/25/97 | Sytkowski et al. | 424 | 85.1 | |
| | AM | 5,571,787 | 11/5/96 | O'Brien et al. | 514 | 12 | |
| | AN | 5,457,089 | 10/10/95 | Fibi et al. | 514 | 8 | |
| | AO | 4,835,260 | 5/30/89 | Shoemaker | 530 | 397 | |
| | AP | 4,806,524 | 2/21/89 | Kawaguchi et al. | 514 | 8 | |
| RW | AQ | 4,703,008 | 10/27/87 | Lin | 435 | 240.2 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|----|----|-----------------|----------|--------------------------------------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| RW | AR | WO 00/35475 | 6/22/00 | PCT (in German w/English abstract) | — | — | X | |
| | AS | WO 98/18926 | 5/7/98 | PCT | — | — | | |
| | AT | WO 97/32895 | 12/12/97 | PCT | — | — | | |
| RW | AU | WO 97/18318 | 5/22/97 | PCT (in Japanese w/English abstract) | — | — | | X |
| | AV | WO 95/05465 | 2/23/95 | PCT | — | — | | |


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|----|--|
| RW | AW | Bernaudin et al., 1999, "A potential role for erythropoietin in focal permanent cerebral ischemia in mice", J. Cereb. Blood Flow Metab. 19:643-651 |
| | AX | Bondy, 1995, "The relaxation of oxidative stress and hyperexcitation to neurological disease", Proc. Soc. Exp. Biol. Med. 208:337-345 |
| | AY | Brines et al., 2000, "Erythropoietin crosses the blood-brain barrier to -protect against experimental brain injury", Proc. Natl. Acad. Sci. USA 97:10526-10531 |
| RW | AZ | Campana et al., 1998, "Identification of a neurotrophic sequence in erythropoietin", Int. J. Mol. Med. 1:235-241 |

Re: In re Brines


6/4/02

page 10:4

| | | |
|---|----|--|
|  | | Digicaylioglu et al. 1995, "Localization of specific erythropoietin binding sites in defined areas of the mouse brain.", Proc. Natl. Acad. Sci. USA <u>92</u> :3717-3720 |
| | BB | Dipaolo et al., 1992, "Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment", ASAIO J. <u>38</u> :M477-M480 |
| | BC | Grimm et al., 1990, "Improvement of brain function in hemodialysis patients treated with erythropoietin", Kidney Intl. <u>38</u> :480-486 |
| | BD | Hefti, 1997, "Pharmacology of neurotrophic factors", Annu. Rev. Pharmacol. Toxicol. <u>37</u> :239-267 |
| | BE | Hengemihle et al., 1996, "Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice", Physiol. Behav. <u>59</u> :153-156 |
| | BF | Hirakata et al., 1992, "CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO", Am. J. Physiol. <u>262</u> :F737-F743 |
| | BG | Juul et al., 1998, "Erythropoietin and erythropoietin receptor in the developing human central nervous system", Pediatr. Res. <u>43</u> :40-49 |
| | BH | Konishi et al., 1993, "Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo", Brain Res. <u>609</u> :29-35 |
| | BI | Kopf et al., 1994, "Memory-improving actions of glucose: involvement of a central cholinergic muscarinic mechanism.", Behav. Neural Biol. <u>62</u> :237-243 |
| | BJ | Latini et al., 1998, "Comparative efficacy of a DA2/ α 2 agonist and a β -blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusion", J. Cardiovasc. Pharmacol. <u>31</u> :601-608 |
| | BK | Li et al., 1998, "A single pre-training glucose injection induces memory facilitation in rodents performing various tasks: contribution of acidic fibroblast growth factor", Neurosci. <u>85</u> :785-794 |
| | BL | Lipinski et al., 1995, "Nerve growth factor facilitates conditioned taste aversion learning in normal rats", Brain Res. <u>692</u> :143-153 |
| | BM | Liu et al., 1997, "Regulated human erythropoietin receptor expression in mouse brain", J. Biol. Chem. <u>272</u> :32395-32400 |
| | BN | Liu et al., 1994, "Tissue specific expression of human erythropoietin receptor in transgenic mice", Devel. Biol. <u>166</u> :159-169 |
| | BO | Marrero et al., 1998, "Erythropoietin receptor-operated Ca^{2+} channels: activation by phospholipase C- γ 1", Kidney Intl. <u>53</u> :1259-1268 |
| | BP | Marsh et al., 1991, "rHuEPO treatment improves brain and cognitive function of anemic dialysis patients", Kidney Intl. <u>39</u> :155-163 |
| | BQ | Marti et al., 1997, "Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain", Kidney Intl. <u>51</u> :416-418 |
| | BR | Marti et al., 1996, "Erythropoietin gene expression in human, monkey and murine brain", Eur. J. Neurosci. <u>8</u> :666-676 |
| | BS | Masuda et al., 1997, "Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes", Brain Res. <u>746</u> :63-70 |
| | BT | Masuda et al., 1994, "A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes", J. Biol. Chem. <u>269</u> :19488-19493 |
| | BU | Masuda et al., 1993, "Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells", J. Biol. Chem. <u>268</u> :11208-11216 |

OIPE
 NOV 21 2000
 1998-2000
 REMARKS
 75

| | | |
|--|----|--|
| | | Morishita et al., 1997, "Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents <i>in vitro</i> glutamate-induced neuronal death", <i>Neurosci.</i> <u>76</u> :105-116 |
| | | Moss and Scholey, 1996, "Oxygen administration enhances memory formation in healthy young adults", <i>Psychopharmacol.</i> <u>124</u> :255-260 |
| | BX | Nakamura et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", <i>Am. J. Med. Sci.</i> <u>315</u> :199-201 |
| | BY | Nissenson et al., 1991, "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", <i>Ann. Int. Med.</i> <u>114</u> :402-416 |
| | BZ | Nissenson, 1989, "Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life", <i>Sem. Nephrol.</i> <u>9</u> (suppl. 2):25-31 |
| | CA | Ogden, 1989, "Monitoring considerations in recombinant human erythropoietin therapy", <i>Sem. Nephrol.</i> <u>9</u> (suppl. 2):12-15 |
| | CB | Pardridge, 1997, "Drug delivery to the brain", <i>J. Cerebral Blood Flow Metab.</i> <u>17</u> :713-731 |
| | CC | Pardridge et al., 1991, "Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier <i>in vivo</i> ", <i>J. Pharmacol. Exp. Ther.</i> <u>27</u> :66-70 |
| | CD | Poduslo et al., 1994, "Macromolecular permeability across the blood-nerve and blood-brain barriers", <i>Proc. Natl. Acad. Sci. USA</i> <u>91</u> :5705-5709 |
| | CE | Prendergast et al., 1997, "Nitric oxide synthase inhibition impairs spatial navigation learning and induces conditioned taste aversion", <i>Pharmacol. Biochem. Behav.</i> <u>57</u> :347-352 |
| | CF | Rose and Audus, 1998, "Receptor-mediated angiotensin II transcytosis by brain microvessel endothelial cells", <i>Peptides</i> <u>19</u> :1023-1030 |
| | CG | Sadamoto et al., 1998, "Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery", <i>Biochem. Biophys. Res. Comm.</i> <u>253</u> :26-32 |
| | CH | Sakanaka et al., 1998, " <i>In vivo</i> evidence that erythropoietin protects neurons from ischemic damage", <i>Proc. Natl. Acad. Sci. USA</i> <u>95</u> :4635-4640 |
| | CI | Tabira et al., 1995, "Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons <i>in vitro</i> ", <i>Int. J. Devl. Neurosci.</i> <u>13</u> :241-252 |
| | CJ | Wolcott et al., 1989, "Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients", <i>Am. J. Kidney Dis.</i> <u>14</u> :478-485 |
| | CK | Wu and Pardridge, 1999, "Neuroprotection with noninvasive neurotrophin delivery to the brain", <i>Neurobiol.</i> <u>96</u> :254-259 |
| | CL | Yamaji et al., 1996, "Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA", <i>Eur. J. Biochem.</i> <u>239</u> :494-500 |

| | |
|---|---------------------------|
| EXAMINER  | DATE CONSIDERED 6/4/02 |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

PAPER NO: 4